Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension

Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.2165/11586570-000000000-00000

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Amides /administration & dosage; Angiotensin Receptor Antagonists /administration & dosage; Angiotensin-Converting Enzyme Inhibitors /administration & dosage; Drug Therapy, Combination; Female; Fumarates /administration & dosage; Health Care Costs; Health Resources /utilization; Humans; Hypertension /drug therapy; Male; Medication Adherence; Middle Aged

AccessionNumber
22011000418

Date bibliographic record published
13/04/2011